Intermittent/alternated therapy with tamoxifen and medroxy-progesterone acetate prolongs time to resistance to tamoxifen without benefit for (progression free) survival in patients with advanced breast cancer. Results of an EORTC phase III study (trial 10863)

✍ Scribed by L Beex; C Rose; H Mouridsen; J Jassem; M Nooy; J Estape; R Paridaens; M.J Piccart; T Gorlia; L Baila

• Book ID: 118622191
• Publisher: Elsevier Science
• Year: 2004
• Tongue: English
• Weight: 172 KB
• Volume: 2
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(04)90843-9